Osmotica Pharmaceutical (United States)
- Research works
- 4 ▲ 245% vs 2013–17
- Citations
- 19 5.1 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 23% world 28%
Not ranked overall: Osmotica Pharmaceutical (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Osmotica Pharmaceutical (United States) publish most on?
By volume in 2022–2025: Parkinson's Disease Mechanisms and Treatments, Botulinum Toxin and Related Neurological Disorders and Autism Spectrum Disorder Research.
- 1 Parkinson's Disease Mechanisms and Treatments Neurology 0 works
- 2 Botulinum Toxin and Related Neurological Disorders Neurology 0 works
- 3 Autism Spectrum Disorder Research Cognitive Neuroscience 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Osmotica Pharmaceutical (United States)'s research output changed?
Output in 2018–2022 was 245% higher than in 2013–2017.
Other research institutions in Wilmington
- University of North Carolina Wilmington
- Pharmaceutical Product Development (United States)
- New Hanover Regional Medical Center
- Coastal Area Health Education Center
- TranS1 (United States)
- Human Immunome Project
- Cortech Solutions (United States)
- Onto Innovation (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.